Usana Health Sciences Inc (USNA) Stock Price & Analysis
Usana Health Sciences Inc (USNA) rose 1.66% to USD 19.01 as of June 10, 2026 at 07:19 UTC, according to Nexqual real-time market data.
USNA last closed at USD 18.7; the session ranged USD 18.38–19.29 on volume of 92,130 shares. Market capitalization is $350.98M, with a 52-week range of USD 16.6–38.32 (NYQ). Source: Nexqual, June 10, 2026 at 07:19 UTC.
Key Statistics (as of June 10, 2026 at 07:19 UTC)
| Price | USD 19.01 |
|---|---|
| Change | ▲ 1.66% (up) |
| Previous Close | USD 18.7 |
| Open | USD 18.71 |
| Day Range | USD 18.38 – 19.29 |
| 52-Week Range | USD 16.6 – 38.32 |
| Volume | 92,130 shares |
| Market Cap | $350.98M |
| Exchange | NYQ |
Technical Analysis (USNA)
Nexqual's technical model rates USNA "BUY" based on 4 bullish and 1 bearish signals across 123 daily candles, as of June 10, 2026 at 07:19 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 52.41 (neutral) |
| vs SMA50 | Above (USD 18.46) |
| MACD | -0.1 (negative) |
Analyst Ratings (USNA)
Wall Street analysts rate USNA "None" based on 1 analysts, with a mean price target of USD 39 (range USD 39–39), per Nexqual as of June 10, 2026 at 07:19 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 1 |
| Mean Target | USD 39 |
| High Target | USD 39 |
| Low Target | USD 39 |
| Buy / Hold / Sell | 0 / 0 / 0 |
Earnings (USNA)
| Next Earnings Date | 2026-07-21 |
|---|---|
| EPS Estimate | USD 0.43 |
| Revenue Estimate | $235.00M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 0.61 vs est 0.44 ▲ beat |
| 2025-12-31 | USD 0.6 vs est 0.41 ▲ beat |
| 2025-09-30 | USD -0.15 vs est -0.15 ▲ beat |
| 2025-06-30 | USD 0.74 vs est 0.54 ▲ beat |
Source: Nexqual, June 10, 2026 at 07:19 UTC.
Financials & Fundamentals (USNA)
| Total Revenue | $925.94M |
|---|---|
| Revenue Growth (YoY) | +0.30% |
| Gross Margin | +77.55% |
| Operating Margin | +5.54% |
| Profit Margin | +0.96% |
| ROE | +1.55% |
| Debt / Equity | 2.35 |
| Current Ratio | 2.51 |
| Total Cash | $162.75M |
| Total Debt | $14.00M |
| Free Cash Flow | $29.57M |
Source: Nexqual, June 10, 2026 at 07:19 UTC.
Financial Health Score (USNA)
Nexqual rates Usana Health Sciences Inc's overall financial health "Solid" across five dimensions, as of June 10, 2026 at 07:19 UTC.
| Growth | Solid — Revenue +8% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 78%, operating 6% |
| Balance Sheet | Strong — $163M cash vs $14M debt, net cash position |
| Cash Flow | Mixed — FCF $30M, slim 3.2% margin |
| Efficiency | Weak — ROE 2%, ROA 4.1% |
Ownership (USNA)
| Insider Ownership | +40.86% |
|---|---|
| Institutional Ownership | +56.59% |
| Shares Outstanding | 18.46M |
| Float | 9.85M |
| Short % of Float | +5.87% |
Source: Nexqual, June 10, 2026 at 07:19 UTC.
Leadership (USNA)
Usana Health Sciences Inc is led by Kevin G. Guest (age 62), CEO & Executive Chairman, per Nexqual as of June 10, 2026 at 07:19 UTC.
| CEO & Executive Chairman | Kevin G. Guest (age 62) |
|---|---|
| Chief Financial Officer | G. Douglas Hekking (age 55) |
| Chief Operating Officer | Walter Noot (age 59) |
| Founder & Chairman Emeritus | Myron W. Wentz (age 84) |
| Executive Director of Product Development & Technology | John Cuomo |
Major Backers & Investors (USNA)
Notable institutional backers of Usana Health Sciences Inc include Pzena Investment Management LLC, Renaissance Technologies, Nantahala Capital Management, LLC, according to Nexqual as of June 10, 2026 at 07:19 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Pzena Investment Management LLC | 6.01% |
| Renaissance Technologies | 5.51% |
| Nantahala Capital Management, LLC | 4.39% |
| Charles Schwab Investment Management, Inc. | 1.8% |
| AQR Capital Management, LLC | 1.61% |
| DFA INVESTMENT DIMENSIONS GROUP INC-U.S. Small Cap Value Portfolio | 1.51% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 8.42% |
| Vanguard Group | 7.64% |
| Dimensional Fund Advisors | 4.52% |
| Geode Capital | 1.43% |
Source: Nexqual, June 10, 2026 at 07:19 UTC.
From Usana Health Sciences Inc's Latest SEC 10-K Filing (filed 2026-03-16)
Key Strengths & Strategy (as disclosed to the SEC)
- USANA Health Sciences, Inc. develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe.
- It operates in two segments, Core nutritional and Hiya Direct-To-Consumer.
- The company offers USANA nutritional optimizers, including supplements for cardiovascular health, skeletal/structural health, and digestive health; Essentials/CellSentials, such as vitamin and mineral supplements for age group beginning with children 13 months of age; and food products that include meal replacement shakes, snack bars, and other related products for healthy weight management, digestive health, and energy and hydration.
- It offers Celavive, a skincare regimen for various skin care types and ethnicities; and all other products comprising materials and online tools for associates to build business and marketing of products The company sells its products through retail customers, a subscription model, and direct selling, as well as online.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| NUS | Nu Skin Enterprises, Inc. | USD 5.44 | ▲ 1.3% |
| JBSS | John B. Sanfilippo & Son, Inc. | USD 76.86 | ▲ 1.92% |
| IPAR | Interparfums, Inc. | USD 96.86 | ▲ 6.12% |
| WRLD | World Acceptance Corporation | USD 169.5 | ▲ 1.32% |
| NATR | Nature's Sunshine Products, Inc | USD 20.14 | ▲ 1.77% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 07:19 UTC. This page is informational and not investment advice.